GPER1 and breast cancer: In addition to the selective estrogen receptor modulator tamoxifen, the complete ERα antagonist Fulvestrant (ICI 182,780) binds to GPER and activates signaling pathways in breast cancer cells, thus leading to the stimulation of proliferation (68).